David Paez-Espino, Co-founder & CTO at Ancilia Biosciences, discusses the use of CRISPR technology to develop a new class of bacterial therapies that address critical gaps in microbiome-based treatments.
Seres Therapeutics, a leader in the live biotherapeutics space, has received pivotal feedback from the U.S. Food and Drug Administration (FDA) regarding the development of its lead investigational treatment, SER-155,…
Researchers have developed a new approach to restore the gut microbiota by combining a high-fiber, plant-based diet with supplementation of beneficial microbes such as Limosilactobacillus reuteri.
The microbiota plays a protective role against colorectal cancer by regulating Snhg9.
Understanding the vaginal microbiome is essential not only for treating gynecological conditions but also for preventing them and promoting overall well-being.
Chris Ford, Senior Vice President, Translational Biology at Seres Therapeutics, discusses the development of SER-155, a cultivated bacterial consortium designed to address the unmet medical need of preventing bloodstream infections…
By suggesting that BA–MCYs can regulate the production of bile acids, the findings of a recent study offer insights for treating metabolic conditions such as diabetes.
Specific microbial metabolites can lead to new therapies for skin barrier disorders such as eczema and psoriasis.
A comprehensive look at the gut microbiome’s structure, functions, and strategies for sustaining its health.
The discussion with Professor Alessio Fasano highlights the complex interplay between homeostatic, hedonic, and microbiota-driven mechanisms in regulating hunger.
